Molecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need?

Current Urology Reports
Michael Garcia-RoigVinata Lokeshwar

Abstract

Renal cell carcinoma (RCC) is largely diagnosed incidentally on imaging taken for unrelated reasons. The management of localized lesions is primarily extirpative with excellent results. Treatment of advanced RCC has evolved over recent years with the use of targeted therapies such as tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, and antibody-mediated therapies. The treatment response to these targeted therapies is highly variable, with no clear clinical method of identifying patients who will benefit from or not tolerate therapy. The field of molecular markers has evolved significantly in the last decade, with a multitude of markers identified that predict treatment response and drug toxicity. The following review critically evaluates those molecular markers that have been assessed for their utility in predicting treatment response in patients with advanced/metastatic renal cell carcinoma (mRCC). Identifying the ideal treatment for these patients will improve responses to therapy, minimize morbidity, and save significant healthcare dollars.

References

Dec 1, 1982·American Journal of Clinical Oncology·M M OkenP P Carbone
May 1, 1994·Nature Genetics·J R GnarraF M Duh
Jan 27, 2000·The Journal of Urology·R J Motzer, P Russo
Oct 12, 2000·Nature Cell Biology·G BergersD Hanahan
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerMadhu Mazumdar
Sep 21, 2002·Molecular and Cellular Biology·Christine C HudsonRobert T Abraham
Nov 21, 2002·The Annals of Thoracic Surgery·Joachim PfannschmidtHendrik Dienemann
Mar 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Susan HalabiNicholas J Vogelzang
Aug 2, 2003·The New England Journal of Medicine·James C YangSteven A Rosenberg
Feb 10, 2004·The Journal of Urology·Robert C FlaniganE David Crawford
Mar 1, 2005·The Annals of Thoracic Surgery·Sudish C MurthyEugene H Blackstone
Jun 8, 2006·JAMA : the Journal of the American Medical Association·Robert J MotzerM Dror Michaelson
Oct 19, 2006·Journal of the American College of Cardiology·Christopher J BoosAndrew D Blann
Dec 7, 2006·Journal of the National Cancer Institute·George CusatisSharyn D Baker
Jan 11, 2007·Clinical Therapeutics·Ted Shih, Celeste Lindley
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Mar 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laura Q M Chow, S Gail Eckhardt
May 19, 2007·The Journal of Urology·Brian I Rini, Steven C Campbell
Jul 5, 2007·BJU International·Johanna SandlundTorgny Rasmuson
Sep 19, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ronald M BukowskiDavid McDermott
May 9, 2008·International Journal of Cancer. Journal International Du Cancer·Jean-Jacques PatardAllan J Pantuck
Aug 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I RiniDaniel J George
Nov 11, 2008·The Urologic Clinics of North America·Paul Russo, Matthew Francis O'Brien
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bernard EscudierRonald M Bukowski
Aug 18, 2009·The Journal of Urology·Steven C CampbellUNKNOWN Practice Guidelines Committee of the American Urological Association
Mar 6, 2010·BJU International·Benjamin NamdarianChristopher M Hovens
Jul 2, 2010·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·Ryu KanzakiKen Kodama
Jul 17, 2010·European Urology·Börje LjungbergUNKNOWN European Association of Urology Guideline Group
Jul 21, 2010·The Journal of Urology·Nicholas J HellenthalHyung L Kim
Jul 24, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Carol PeñaRonald M Bukowski
Nov 26, 2010·Journal of Laparoendoscopic & Advanced Surgical Techniques. Part a·Adam C MuesJaime Landman
Apr 6, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A J ZuritaJ V Heymach
Apr 13, 2011·International Journal of Urology : Official Journal of the Japanese Urological Association·Hai-Liang ZhangDing-Wei Ye

❮ Previous
Next ❯

Citations

Jan 13, 2016·Cancer Immunology, Immunotherapy : CII·Anastasia DielmannAntonia Busse
Aug 15, 2014·Frontiers in Oncology·Zofia Felicja BieleckaCezary Szczylik
Jan 23, 2017·Current Urology Reports·Marina O GolovastovaAndrey A Zamyatnin
Oct 22, 2015·Drugs·Gillian M Keating
Nov 15, 2016·Oncology Reports·Yasushi NakaiKiyohide Fujimoto
Jan 27, 2019·Drugs & Therapy Perspectives : for Rational Drug Selection and Use·Katherine A Lyseng-Williamson
Oct 20, 2018·Cancer Cell International·Binghai ChenTao Guo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.